Search Results
May 07, 2026, 10:54 ET Advaita Bio bringt iSCanGuide™ auf den Markt: Vereinheitlichte Analyse für Einzelzell-Transkriptomik und räumliche Transkriptomik, gestützt auf GPU-beschleunigte Infrastruktur
vollständiger Unterstützung für 10x Genomics Visium (Standard/HD) und Xenium. Räumliche Zellverteilungen lassen sich visualisieren und räumlich variable Gene identifizieren, und zwar innerhalb derselben Umgebung, die für Einzelzell-RNA-seq verwendet wird, ohne dass ein Datenexport erforderlich ist.Integrierte
More news about: Advaita Bio
May 07, 2026, 09:05 ET UWorld Supports 93 Future Medical Researchers in Partnership with Goldwater Foundation
University in Bowling Green, Kentucky, who plans to study neurology. His research examines spinal cord regeneration using computational analysis of gene expression. He is interested in improving the diagnosis and treatment of atypical Parkinsonian disorders. He works at a crisis hotline and participates
More news about: UWorld, LLC
May 07, 2026, 09:00 ET GI Partners Completes Acquisition of the CDMO and Cell Solutions Businesses from Charles River Laboratories and forms Rose BioSolutions
Laboratories International, Inc., forming Rose BioSolutions ("Rose Bio"), a leading provider of advanced manufacturing capabilities across the cell and gene therapy space.
More news about: GI Partners
May 07, 2026, 08:30 ET Greenland Mines Reports Up To 45% - 55% Increase in Palladium Equivalent (PdEq) Grades at Skaergaard in Sensitivity Study
of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., the Skaergaard
More news about: Greenland Mines Ltd
May 07, 2026, 08:02 ET Ribo und Boehringer Ingelheim treiben ihr siRNA-Programm zur Behandlung der metabolischen Dysfunktion-assoziierten Steatohepatitis (MASH) weiter voran
bieten", sagte Li-Ming Gan, Co-CEO und Global R&D President von Ribo.siRNA-Therapeutika sind darauf ausgelegt, krankheitsverursachende Gene zu stilllegen, indem sie auf deren Boten-RNAs (mRNAs) abzielen. Die Technologie von Ribo zur gezielten Verabreichung in die Leber soll eine selektive
More news about: Suzhou Ribo Life Science Co., Ltd.
May 07, 2026, 08:00 ET Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
effect of sevasemten on safety, biomarkers of muscle damage and function in children and adolescents with Duchenne who have been previously treated with gene therapy. The Company continues to collect longer-term data in the open-label extension portion of these Phase 2 programs to inform the future clinical
More news about: Edgewise Therapeutics
May 07, 2026, 07:45 ET Advaita Bio Launches iSCanGuide™: Unified Single-Cell and Spatial Transcriptomics Analysis, Powered by GPU-Accelerated Infrastructure
annotation, and trajectory analysis, with flexible workflows that adapt to your data at every stage.Spatial Transcriptomics Analysis: Map gene expression in its native tissue context with full support for 10x Genomics Visium (Standard/HD) and Xenium. Visualize spatial cell distributions and
More news about: Advaita Bio
May 07, 2026, 07:45 ET Advaita Bio Launches iSCanGuide™: Unified Single-Cell and Spatial Transcriptomics Analysis, Powered by GPU-Accelerated Infrastructure
annotation, and trajectory analysis, with flexible workflows that adapt to your data at every stage.Spatial Transcriptomics Analysis: Map gene expression in its native tissue context with full support for 10x Genomics Visium (Standard/HD) and Xenium. Visualize spatial cell distributions and
More news about: Advaita Bio
May 07, 2026, 07:05 ET REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
advancement of next-generation gene therapies for rare and retinal diseases, and highlight the company's unique capsid engineering and translational capabilities.Title: NVG82, a capsid engineered for enhanced outer retinal gene transfer when administered
More news about: REGENXBIO Inc.
May 07, 2026, 07:00 ET Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
study of INS1201, an intrathecally delivered gene therapy for patients with Duchenne muscular dystrophy (DMD).INS1202Insmed continues to enroll patients in the Phase 1 ARMOR study of INS1202, an intrathecally delivered gene therapy for patients with amyotrophic lateral
More news about: Insmed Incorporated
May 06, 2026, 22:49 ET Delphi Diagnostics Announces New Publication in the European Journal of Cancer
from the PACS-01 clinical trial, demonstrates that EAIRR provides meaningful prognostic and endocrine-predictive information beyond the 21-gene Recurrence Score (RS).Key HighlightsConfirms that EAIRR adds statistically significant prognostic information
More news about: Delphi Diagnostics Inc
May 06, 2026, 17:23 ET Coreia e falta de equilíbrio são os sintomas que mais impactam a vida de pacientes com Doença de Huntington, alerta pesquisa com o apoio da farmacêutica Teva Brasil
participação da sociedade civil.Não existem estatísticas oficiais sobre a DH no Brasil, mas estima-se que cerca de 13 mil a 19 mil pessoas tenham o gene da doença, e entre 65 mil e 95 mil apresentem risco de ter a enfermidade por serem descendentes de portadores, segundo a Biblioteca Virtual em Saúde
More news about: Teva Brasil
May 06, 2026, 17:11 ET /C O R R E C T I O N -- Mana.bio/
AI-Driven LNP PlatformT-Cell In Vivo Engineering Data to Be Presented at the 2026 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)TEL AVIV, Israel and BOSTON, May 6, 2026
More news about: Mana.bio
May 06, 2026, 16:30 ET Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey,
More news about: Insmed Incorporated
May 06, 2026, 16:26 ET IMMP Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Immutep Limited
(NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. The company's product pipeline includes TACTI-004, which is in phase III clinical
More news about: Robbins LLP
May 06, 2026, 16:05 ET Castle Biosciences Reports First Quarter 2026 Results
Comprehensive Cancer Network® (NCCN) threshold for forgoing sentinel lymph node biopsy and outperforms traditional staging criteria and other predictive gene expression profile (GEP) tests. See the Company's
More news about: Castle Biosciences, Inc.
May 06, 2026, 09:29 ET Partner Therapeutics Announces Receipt of FDA Commissioner's National Priority Voucher for BIZENGRI® (Zenocutuzumab-zbco) in NRG1 Fusion-Positive Cholangiocarcinoma
actionable gene fusions like NRG1. About BIZENGRI (zenocutuzumab-zbco) INDICATIONS BIZENGRI is indicated for the treatment of adults with advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with
More news about: Partner Therapeutics, Inc.
May 06, 2026, 09:00 ET Genesis AI Unveils GENE-26.5, the First AI Brain to Enable Robots with Human-Level Physical Manipulation Capabilities
full-stack robotics company, today announced GENE-26.5, the first robotic brain to give robots human-level physical manipulation capabilities. Alongside it, Genesis AI introduced a first-of-its-kind system to unlock unlimited amounts of data and train GENE-26.5 at scale. The system combines two proprietary
More news about: Genesis AI
May 06, 2026, 09:00 ET Benchling Launches One-Click Ordering for Biopharma R&D with Twist Bioscience, Adaptyv, and Ginkgo Bioworks
Twist Bioscience for gene synthesis, antibody expression, binding, developability and other characterization services,
More news about: Benchling
May 06, 2026, 09:00 ET Modicus Prime Raises $8M to Enable AI Audit Readiness Across Pharma
enable AI audit readiness at scale. The platform integrates with existing tech stacks and quality management systems, supporting biologics, cell and gene therapies, and vaccine manufacturing across global regulatory environments.About Frist Cressey PartnersFounded by former U.S.
More news about: Modicus Prime
May 06, 2026, 08:00 ET Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant
More news about: Actinium Pharmaceuticals, Inc.
May 06, 2026, 07:30 ET Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
center of this biology. Studies have shown SCD1 upregulation in experimental heart failure and linked cardiac SCD activity to lipid overload, collagen gene expression, hypertrophy, and cardiac dysfunction, while SCD also influences angiogenesis and energy metabolism in the hypoxic myocardium after myocardial
More news about: Galmed Pharmaceuticals Ltd.
May 06, 2026, 07:05 ET REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy
Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases,
More news about: REGENXBIO Inc.
May 06, 2026, 07:00 ET (E,E)-bisantrene Discovered to Function via Silencing of c-MYC Expression
stabilizes G4 DNA structures within the c-MYC gene promoter region, resulting in potent suppression of c-MYC expression and broad cytotoxic activity in a wide range of cancer models.[1][2]The MYC protein functions as a master regulator of gene expression, governing thousands of genes involved
More news about: Racura Oncology
May 05, 2026, 16:30 ET Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029
was down 2% year over year, primarily driven by lower Sanger Sequencing revenue, partially offset by higher revenue in Next Generation Sequencing and Gene Synthesis.Summary of GAAP Earnings Results - Continuing OperationsOperating loss was $165.8
More news about: Azenta